Research and Clinical Trials

Brief Description  
Phase III Clinical Trial to evalute if the addition on Temozolomide (a type of oral chemotherapy) to radiation followed by Temozolomide is more effective than radiation alone in patients who have symptomatic or progressive grade 2 gliomas.
Who may be Eligible  

Patients must meet the following inclusion criteria to be eligible to enter the study:

  • Diagnosis of grade 2 astrocytoma, oligodendroglioma or oliogoastrocytoma
  • Pathology available for submission to confirm diagnosis and determination of 1p/19q deletion status
  • History & physical and neurological
  • MRI scans, (if unable to undergo MRI, not eligible)
  • Karnofsky performance status>60
  • Blood tests (liver, kidney and blood counts) and pregnancy test if indicated
  • no previous radiation to the head and scalp
  • no prior invasive malignancy within the past 3 years
IRB Number  
Principal Investigator  
Crimaldi, Anthony

For More Information, Contact  Donna  , Couture-Johnson
Phone:  (704) 355-1677  Fax:  (704) 355-1188  
Address:PO Box 32861 Charlotte, NC 28232